Aktis Oncology, a Cambridge, MA-based biotechnology company focused on advancing alpha radiopharmaceuticals to treat solid cancers, raised $84M in Series A funding.
The round was led by Cowen Healthcare Investments, MRL Ventures Fund, ArrowMark Partners, Mirae Asset Venture Investment, Timefolio Capital, Pappas Capital, MPM Capital, Vida Ventures, EcoR1 Capital, Octagon Capital, TCG Crossover, Bristol Myers Squibb, and Novartis. Aktis also announced that in conjunction with the Series A Extension, Kevin Raidy, Managing Partner at Cowen Healthcare Investments and Jason Ruth, Partner at MRL Ventures will be joining Aktis’ Board of Directors as Observers.
The company intends to use the funds to develop proprietary targeted alpha radiopharmaceutical pipeline for the treatment of highly prevalent cancers.
Led by CEO Matthew Roden, Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology’s molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment.
FinSMEs
26/08/2022